Status: current, Sufficiently defined by necessary conditions definition status. Date: 31-Jul 2018. Module: SNOMED CT core module
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 3650012013 | Prolonged-release cutaneous patch (dose form) | en | Fully specified name | Active | Entire term case insensitive | SNOMED CT core module |
| 3650013015 | Prolonged-release cutaneous patch | en | Synonym | Active | Entire term case insensitive | SNOMED CT core module |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| Prolonged-release cutaneous patch | Is a | Cutaneous dose form | true | Inferred relationship | Existential restriction modifier | ||
| Prolonged-release cutaneous patch | Has dose form administration method | Apply | true | Inferred relationship | Existential restriction modifier | ||
| Prolonged-release cutaneous patch | Has dose form transformation | No transformation | true | Inferred relationship | Existential restriction modifier | ||
| Prolonged-release cutaneous patch | Has dose form intended site | Cutaneous | true | Inferred relationship | Existential restriction modifier | ||
| Prolonged-release cutaneous patch | Has dose form release characteristic | Prolonged-release | true | Inferred relationship | Existential restriction modifier | ||
| Prolonged-release cutaneous patch | Has basic dose form | Patch | true | Inferred relationship | Existential restriction modifier |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
| Product containing precisely menthol 30 microgram/1 milligram and methyl salicylate 100 microgram/1 milligram conventional release cutaneous patch (clinical drug) | Has manufactured dose form | False | Prolonged-release cutaneous patch | Inferred relationship | Existential restriction modifier |
This concept is not in any reference sets
FHIR